Hims & Hers: The Messy Middle

Travis Hoium
11-12

Shares of $Hims & Hers Health Inc.(HIMS)$ ( ▲ 8.78% ) have fallen nearly 30% over the past week, which isn’t the performance I’m looking for from what was the biggest holding in the Asymmetric Portfolio.

There were some positives in the company’s third-quarter 2026 results, but under the headline growth rate, there was a lot to be desired on several fronts, so the market’s reaction was understandable.

The question for investors now isn’t whether Q3 was good or if Q4 will be better (it probably won’t be). Attention now turns to 2027. Management explicitly stated that it’s saving dry powder for a big push in 2027. If that works, this could be a leader in the booming peptide market and get lifelong customers who come in through labs, peptides, GLP-1s, and TRT.

But if it doesn’t work, the customer acquisition treadmill will continue, and Hims & Hers won’t be the potential winner I think it can be.

Here’s a look at what I saw this quarter.

Looking Backward

I’m going to start with the results and the bad news for Hims & Hers.

  • Subscribers fell 100,000 in Q3

  • Gross margin plunged from 73.8% a year ago to 57.2%

  • Guidance for 2030 was not reiterated on the call or in the earnings release

    • Previous guidance given was $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030

    • Note: This guidance was included in a presentation sent out after the market closed on Tuesday…odd.

  • Guidance is for a slight sequential drop in revenue in Q4 2026

You can see both the positive trends and the challenges below. Revenue was up 49% from a year ago to $890 million, driven by the Eucalyptus acquisition.

But Hims & Hers is giving up margin. This is driven by a move into international markets and the shift to more branded GLP-1s, which come with much lower margins.

The negative way to look at this is that competition is eating away at Hims & Hers’ market share, and there’s not as much ongoing loyalty from customers as I may have thought.

Ro has gained share; we know that. But it’s also spent on massive sponsorship deals to acquire that growth. Hims & Hers have said they didn’t want to play the Ro game, at least for now.

The subscriber drop was stark and probably the biggest red flag in results. You can see it also coincided with a jump in revenue per user, indicating more users are using a higher price point product like GLP-1s. Maybe that’s good…?

I’ll get to why this may not be the negative it seems in a moment, but it’s notable, and if subscribers continue dropping, it’s not good for Hims & Hers. No sugarcoating that.

The most generous look is that Hims & Hers is transitioning from being an individual product sales company to being a platform. If that’s the case, all of the company’s investments in AI and vertically integrating manufacturing haven’t paid off yet, so we’re in a messy middle between being an immature product marketer and a mature health disruption company.

I can make both cases today, and that’s what has the market worried. There’s more perceived risk today than there was a week ago, even if the ultimate prize is potentially getting bigger.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment